Skip to main content

Table 3 Response rates for patients with cirrhosis

From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US

Genotype Treatment Duration (weeks) SVR (%) Trials
1 Telaprevir + Peginterferon-alpha + Ribavirin 12 + 12 or 12 + 36 75 ADVANCE
Harvoni 12 98 ION
Olysio + Sovaldi 24 100 COSMOS
Viekira Pak + Ribavirin 24 95 TURQOUISE
Sofosbuvir + Peginterferon + Ribavirin (Treatment-naïve) 12 80 NEUTRINO
2 Peginterferon + Ribavirin (Treatment-naïve) 24 62 FISSION
Sofosbuvir + Ribavirin (Treatment-naïve) 12 83 FISSION
Sofosbuvir + Ribavirin (Non-responders & Relapsers) 12 60 FUSION
16 78 FUSION
3 Peginterferon + Ribavirin (Treatment-naïve) 24 30 FISSION
Sofosbuvir + Ribavirin (Treatment-naïve) 24 92 FISSION
Sofosbuvir + Ribavirin (Non-responders & Relapsers) 12 19 FUSION
16 61 FUSION